Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2022-04-01 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return detailing movements in securities, specifically focusing on authorized and issued shares, share options, and other share capital changes for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules. The document is structured as a regulatory submission reporting share capital and share option movements for the month ended 31 March 2022. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital movements and related confirmations, which fits the category of Regulatory Filings (RNS) as a general compliance document that does not fit other specific categories like Share Issue/Capital Change (SHA) because it is a routine monthly return rather than a specific capital change event announcement.
2022-04-01 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Ascletis Pharma Inc. regarding the grant of share options to a participant under the company's share option scheme. It references the Listing Rules of the Hong Kong Stock Exchange and provides details such as the grant date, number of shares, exercise price, and validity period. The document is relatively short (2728 characters) and focuses solely on the share option grant event. It does not contain financial statements, management discussion, or other report content. This fits the definition of a Share Issue/Capital Change announcement, as it relates to the issuance of share options, which is a capital change event.
2022-03-31 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL OF ASC42, AN IN-HOUSE DEVELOPED, BEST-IN-CLASS FXR AGONIST FOR CHRONIC HEPATITIS B INDICATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the completion of patient enrollment in a Phase II clinical trial for a drug candidate ASC42. It provides details about the trial design, safety observations, and the drug's mechanism of action. There are no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (4319 characters) and serves as an update or announcement rather than a formal report or filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement related to clinical trial progress, which is a general regulatory or corporate announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-03-30 English
RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021
Annual Report Classification · 100% confidence The document is a detailed announcement of audited consolidated financial results for the year ended 31 December 2021, including comprehensive financial statements such as the consolidated statement of profit or loss, statement of financial position, notes to the consolidated financial statements, segment information, and accounting policies. It contains actual financial data and analysis for the full fiscal year, not just a summary or announcement of a report. The presence of audited financial results and detailed notes indicates this is the official annual report covering company activity and full financial performance for the year. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-03-29 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES THE LATEST RESULTS OF THE PRECLINICAL STUDIES OF TWO NOVEL ANTI-CANCER DRUG CANDIDATES, ASC61 AND ASC60, TO BE PRESENTED AT AACR ANNUAL MEETING 2022
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the latest preclinical study results of two novel anti-cancer drug candidates, ASC61 and ASC60, which are to be presented at the AACR Annual Meeting 2022. It includes details about the abstracts, presentation types, session categories, and presentation times. The document does not contain financial data, regulatory filings, or formal report content. It is an announcement of scientific research results and upcoming presentations rather than a financial or regulatory report. The length is 4566 characters, which is relatively short and consistent with an announcement. Therefore, this document fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2022-03-27 English
ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
Annual Report Classification · 95% confidence The document is an announcement titled 'ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021' from Ascletis Pharma Inc. It contains detailed financial highlights including revenue, gross profit, loss before tax, and loss for the year, with comparative figures for the previous year. It also includes a comprehensive business review, pipeline updates, and management discussion and analysis sections. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes audited condensed consolidated annual results and detailed operational progress, which aligns with the characteristics of an Annual Report. There is no indication that this is merely an announcement of a report or a certification document. Therefore, the document should be classified as an Annual Report (10-K). FY 2021
2022-03-21 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.